← Back to Search

Behavioural Intervention

Attention Bias Modification for Anxiety in Childhood Cancer Survivors

N/A
Recruiting
Led By Nancy Lau, PhD
Research Sponsored by Fred Hutchinson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 15-29 years
Diagnosis of cancer malignancy
Must not have
Cognitively or physically unable to participate in ABM intervention and surveys
Patients on active/curative cancer treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 4 weeks post intervention
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see if a technique called attention bias modification (ABM) can help reduce anxiety in adolescent and young adult cancer survivors. Cancer-related anxiety is a common issue in this population and can

Who is the study for?
This trial is for adolescent and young adult cancer survivors who have experienced anxiety after battling childhood cancer, head and neck cancers, or leukemia. Participants should be comfortable using internet-based applications and willing to engage in interviews and questionnaires.
What is being tested?
The study tests if attention bias modification (ABM) via smartphone apps can reduce anxiety by redirecting focus from negative triggers to neutral or positive stimuli. It includes gratitude exercises and aims to improve the mental health of young cancer survivors.
What are the potential side effects?
Since this intervention involves psychological techniques delivered through a smartphone app, there may not be direct physical side effects. However, participants might experience emotional discomfort or increased anxiety when engaging with the content.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 15 and 29 years old.
Select...
I have been diagnosed with cancer.
Select...
I received cancer treatment aimed at curing me at a specified hospital.
Select...
I am not currently undergoing treatment aimed at curing my cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to take part in specific activities or answer surveys due to physical or cognitive reasons.
Select...
I am currently receiving treatment aimed at curing my cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 4 weeks post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 4 weeks post intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinic recruitment rates
Patient acceptability of ABM: Client Satisfaction Questionnaire (CSQ-8)
Patient acceptability of ABM: System Usability Scale (SUS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (ABM, gratitude/savoring)Experimental Treatment4 Interventions
Patients engage in ABM over 10 minutes BIW and respond daily to text messaging prompts to complete gratitude/savoring activity for 4 weeks.
Group II: Arm II (intert attention task)Active Control3 Interventions
Patients engage in inert attention task sessions over 10 minutes BIW for 4 weeks. Patients also receive and respond to text messaging prompts about their mood QD for 4 weeks. After completion of the 4 week follow up survey, patients are given access to all components of ABM + gratitude/savoring sessions and texts on study.

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer CenterLead Sponsor
570 Previous Clinical Trials
1,340,183 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,017,941 Total Patients Enrolled
Nancy Lau, PhDPrincipal InvestigatorFred Hutch/University of Washington/Seattle Children's Cancer Consortium
~40 spots leftby Dec 2026